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INTRODUCTION
Major depressive disorder (MDD) is a common and debili-
tating illness resulting in functional disability, decrease in 
quality of life, and increase in healthcare costs.1 MDD is also 
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the third leading cause of moderate to severe disability and of 
disease burden worldwide.2 A large array of different class of 
antidepressants are currently available, however, there has 
been a controversy regarding class and individual differences 
in efficacy for treatment of MDD patients among various an-
tidepressants,3,4 although potentially differential points may 
exist between benefits, acceptability, and acquisition cost.5,6 
Despite of sufficient availability of antidepressants with differ-
ent classes to date, only 30% of patients treated with first anti-
depressant treatment show a symptomatic remission and suf-
fer significant functional impairment.7,8 Such inadequate anti-
depressant efficacy results in suffering from significant residual 
symptoms, functional incapacity, increased utilisation of med-
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ical services, and frequent recurrence and relapse.9-11 
Most guidelines have suggested that such non- or partial re-
sponders should be considered for a switch, combination or 
augmentation of treatment.3,12-14 Among such treatment strate-
gies, augmentation is the use of an non-antidepressant agents 
to broaden or enhance the therapeutic effectiveness of an an-
tidepressant by affecting different neurotransmitter systems 
combining agents with different mechanisms of action and/or 
indications. Traditional augmentation agents, lithium and tri-
iodothyronine (T3), as well as buspirone, dopamine agonists, 
and stimulants have been commonly used for such patient 
population with limited evidence (e.g., weak efficacy, tolera-
bility issues, shortage of controlled clinical trials and official 
approval issues).15 
Atypical antipsychotics such as olanzapine, quetiapine ex-
tended release (XR), and aripiprazole have clearly demonstrat-
ed efficacy as an augmentation agent for MDD patients through 
a number of small-scale, open-label studies or randomized, 
placebo-controlled clinical trials (RCTs). Among such AAs, 
aripiprazole has been the first approved by the U.S. FDA as an 
augmentation therapy to antidepressants for treating MDD 
in November 2007.
Industry-sponsored registration studies involving RCTs 
have been a gold-standard and cornerstone of modern re-
search concerning medical therapies for human to prove cer-
tain medications’ efficacy and safety, however, such rigorous 
research design usually excludes those with substantial medical 
comorbidity and do not allow concomitant medication treat-
ments, which is commonly encountered in routine practice. 
Hence, RCTs are also criticized in lacking external validity and 
it has been asserted that these efficacy studies do not provide 
sufficient information to clinicians in real-world settings.9 In 
addition, they have limitations in terms of the huge study con-
duction cost, loss of professional autonomy, inflation of rating 
scale scores prior to randomization, patient expectations of 
improvement, unexpected influence by a sponsorship, lack of 
staff and training, observer biases among investigators, a lon-
ger time- frame for conduction and difficulties with randomi-
sation or recruitment, e.t.c. Hence, the usual and easy way to 
go with such further step of researches is open-label and pro-
spectively designed studies to investigations to explore new 
medication (or new acquisition of indication), to acquire sup-
plemental information about a certain medication, and to fa-
cilitate exploratory and hypothesis-generating studies. 
However, specific information on such open-trials for future 
RCTs or addressing certain clinical issues not to be explained 
or investigated in RCTs is still very lacking today. Hence, the 
objective of the present study is to provide whether open-label 
studies (OLS) may properly foresee the efficacy of RCTs using 
OLSs and RCTs for aripiprazole augmentation (AA) in the 
treatment of MDD, with the use of meta-analysis based on 
published OLSs and RCTs. 
METHODS
Source of data
A search of the studies used the key terms “depression and 
aripiprazole” from the databases of PubMed/PsychInfo from 
Jan 2005 through July 2013. The data were verified for publi-
cation in English-based peer-reviewed journals. We also 
used reference lists from identified articles and reviews to 
find additional studies. Abstracts identified during literature 
search were screened by two review authors independently. 
Potentially eligible papers were read in full by two review au-
thors to determine whether they met the eligibility criteria. 
Disagreements were discussed with a third review author until 
consensus was reached. Study selection was handled first by 
two of the authors, H.J. S and C. H. then independently reas-
sessed by C.U. P.
Inclusion criteria
We included studies of AA in the treatment of MDD. The 
studies to be included in the present meta-analysis should ful-
fill following criteria: 1) prospective design with commonly 
adopted in clinical trials as efficacy measures such as Hamil-
ton Depression Rating scale (HAMD), e.t.c.; 2) at least one or 
more follow-up visit; 3) study duration at least for 4 weeks; 4) 
OLS or RCT for aripiprazole; and 5) published in English-
based peer-reviewed journal. There were no requirements or 
restrictions in search of data for date. However, post-hoc anal-
ysis of RCT, redundant studies, case-report or letter-to-the-ed-
itor concerning interesting or rare case illustration in the use 
of aripiprazole for treating MDD were not included. If neces-
sary, the study authors were contacted for additional informa-
tion. Figure 1 summarizes the disposition of the included 
studies for the present meta-analysis. 
Data extraction
Data on patients (e.g. age and gender), design (e.g. OL, ran-
domization, allocation concealment), duration of treatment 
(weeks), name of antidepressant, range of aripiprazole doses, 
sample size, type of primary outcome measure for efficacy, 
baseline and endpoint mean and standard deviation (SD) of 
primary efficacy measures, remission and response rates based 
on the criteria as each study defined. The baseline and end-
point mean and SD were replaced by baseline ones or taken 
manually calculated from visual availability or taken from stan-
dard errors, confidence intervals (CIs) or t-values if such pa-
rameters were not available from the original study. The pri-
mary efficacy measure was HAMD-17, Montgomery-Åsberg 
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Depression Rating Scale (MADRS), Quick Inventory of De-
pressive Symptomatology-16 items (QIDS-16) in the studies 
included in the present meta-analysis. 
Data analysis
Primary efficacy measure
The primary efficacy measure was the mean change from 
baseline to endpoint in the total scores on HAD-17, MADRS, 
or QIDS which are the most frequently used rating scales in 
the OLS and RCTs included in the present meta-analysis. They 
have been founded to be highly and significantly correlated in 
a number of researches based on a direct comparison of HAMD-
17 and MADRS scores in a rather homogeneous sample.16 
Safety and tolerability
Comparisons of safety and tolerability measures between 
OLSs and RCTs were not done due to very limited and incon-
sistency of reported measures.
Effect size
The effect size for the primary efficacy measures in each 
study were presented as standardized mean differences (SMDs) 
with 95% CI as they were continuous parameters. Cohen’s 
classification was used to evaluate the magnitude of the over-
all effect size with 1) SMD=0.2 to 0.5: small; 2) SMD=0.5 to 
0.8: medium, and 3) SMD >0.8: large effect sizes. The calcula-
tion of SMDs were based on followings: 1) endpoint mean 
primary efficacy score minus baseline primary efficacy score/
pooled SD of the total treatment groups or 2) endpoint mean 
primary efficacy score of the active drug group minus baseline 
primary efficacy score of the placebo group/pooled SD. 
Statistical model 
The random effects model of meta-analysis was applied for 
the analysis since it allows more balance than those under the 
fixed effects model because the smaller studies get more 
weight and the larger studies get less weight as well as allow-
ing for sampling variability with and between studies under 
such model. In general, a random effects model is used to com-
bine subgroups and yield the overall effect. The study-to-study 
variance (tau-squared) is assumed to be the same for all sub-
groups–this value is computed within subgroups and then 
pooled across subgroups.
Heterogeneity and sensitivity analysis
The heterogeneity between studies was analyzed using the I2 
statistics, a measure of how much variance between studies 
can be attributed to differences between studies rather than 
chance. The magnitude of considerable heterogeneity is usual-
ly I2=75–100%. To test the robustness of significant results, 
sensitivity analyses were conducted for studies with high ver-
sus low risk of bias. If statistical heterogeneity was present in 
the respective meta-analysis, subgroup and sensitivity analyses 
were also used to explore possible reasons for heterogeneity: 
judgment on whether one study has a huge impact on the 
721 articles retrieved from database search
----381 from PubMed
----340 from PsychInfo
310 articles excluded since they were not 
depression trials and not based in English
411 articles after exclusion
202 articles excluded since they were reviews and 
book chapter
209 articles after exclusion
150 articles excluded since they were case reports, 
chart reviews, and retrospective studies, and book 
chapter
59 articles into full-text search
37 articles more excluded due to insufficient raw 
data, modeling studies, imaging studies, and 
follow-up studies
23 articles after exclusion
1 RCT: duplicate
4 OLS: anxiety disorder, different endpoint and 
insufficient information
18 articles into meta-analysis
Figure 1. The disposition of selected 
studies for the meta-analysis. RCT: ran-
domized placebo-controlled trial, OLS: 
open-label study.
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overall estimate or underlying influence attributable to the 
overall estimate. To do sensitivity analysis for each study in 
two groups (OLS and RCT), the pooled estimate was repeated-
ly calculated and analyzed with omission of one study at a time. 
Publication bias
The Egger test was also used for detection of publication 
bias to assess the bias associated with the greater likelihood of 
more publication of positive studies than negative studies. We 
adopted the method of Egger since the Egger’s linear regres-
sion method quantifies the bias captured by the funnel plot 
using the actual values of the effect sizes and their precision, 
while Begg and Mazumdar’s test uses ranks. 
Meta-regression
Meta-regression was performed to test the effect of study 
design (OLS vs. RCT) as an independent parameter on the 
mean change in the primary efficacy measure. In this method, 
usually a weighted logistic regression of the 2k cases per study 
is fit where k is the number of study arms, and the weight is 
the number of patients who have or do not have the outcome 
respectively.17 Meta-regression is a sophisticated analytic ap-
proach method merging meta-analytic and linear regression 
principles. It aims to explore whether a linear relationship ex-
ists between an outcome measure and on or more covariates. 
The associations found in a meta-regression should be consid-
ered hypothesis generating and not regarded as proof of cau-
sality.17
Software program for meta-analysis
All directly extracted or computed data from the studies in-
cluded were entered into Comprehensive Meta Analysis ver-
sion 2.0 (CMA v2, Englewood, NJ, USA) to complete meta-
analysis with data synthesis and then analyzed.
RESULTS
Demographics
With the search term and condition, we identified 721 arti-
cles in the PubMed and PsychInfo database. Seven hundred 
and three papers were excluded due to ineligibility, giving. The 
total number of subjects was 990, of which 627 was from RCTs 
and 363 from OLSs. Among the subject male was 317 (197 
from RCTs and 137 from OLSs, 33.7%). The mean subject 
number of OLSs18-30 and RCTs31-35 were 27 and 125.4, respec-
tively. The mean ages of OLSs and RCTs were 48.0 (11.5) and 
43.6 (11.0) years, respectively. The mean duration of trials 
was 9.5 and 7.2 weeks in OLSs and RCTs, respectively. Table 1 
depicts a summary of the studies included in the present meta-
analysis. 
Table 1. The characteristics of the open-label studies and randomized-controlled clinical trials
Duration 
(weeks)
Number of 
subjects (n)
Male (n)
Age (years, 
mean and SD)
Primary efficacy 
rating scale
ARP dose 
(mg/d)
Chen et al.18 4 9 5 38.3 (12.2) HAMD-17 4.2
Fabrazzo et al.19 24 35 14 38.8 (11.5) HAMD-21 5
Sheffrin et al.20 12 24 10 73.9 (6.6) HAMD-17 9.0
Matthews et al.21 7 16 10 41.8 (12.9) HAMD-17 14.4
Hellerstein et al.22 12 15 5 46.1 (13.0) HAMD-24 5–30
Schule et al.23 4 40 13 44.7 (12.6) HAMD-21 15
Rutherford et al.24 6 20 5 63.0 (9.6) HAMD-24 5–15
Patkar et al.25 6 10 4 44.9 (12.2) HAMD-17 13.2
Papakostas et al.26 8 12 4 46.6 (11.3) HAMD-17 ≤30 (mean maximum 
  dose=22.5)
Simon et al.27 8 15 6 44.1 (NA) HAMD-17 2.5–10 (66.7%=10)
Nierenberg et al.28 12 50 19 43.0 (11.0) QIDS-C/S-16 11 at exit
Pae et al. 201329 12 104 37 50.2 (13.1) MADRS 6.6 at exit
Pae et al. 200730 8 13 5 43.3 (11.9) HAMD-17 10.8
Berman et al. 200731 6 182 70 45.6 (11.3) MADRS 11.8 at exit
Berman et al .200932 6 177 39 46.5 (10.6) MADRS 10.7 at exit
Marcus et al.33 6 191 65 44.6 (11.0) MADRS 11.0 at exit
Fava et al.34 8 56 19 45.4 (10.4) MADRS 2 or 5
Lin et al.35 10 21 4 35.9 (10.4) HAMD-17 2.5
HAMD: Hamilton Depression Rating Scale, MADRS: Montgomery-Åsberg Depression Rating Scale, QIDS-C/S-16: 16-item Quick Inventory 
of Depressive Symptomatology Clinician-Rated/Self Rated, ARP: aripiprazole, SD: standard deviation
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Briefly, the clinical benefit of AA for treating patients with 
MDD have been proven in a number of early phase small scale 
OLSs with a use of various primary efficacy rating scales such 
as HAMD, MADRS and QIDS-16.18-24 In the small OLSs, the 
primary endpoint improvement was variable across the stud-
ies due to multiple factors (e.g., patient characteristics, AA 
dose, duration of treatment, e.t.c.); for instance, the cumulative 
remission and response rates showed that, approximately 
60% met criteria for remission and 80% met criteria for re-
sponse at the end of treatment in the recent 12-week OLS,28 
while similar 12-week OLS showed that at the endpoint, the re-
mission rate was 41.3% and the response rate was 55.2%. There 
have been three identically designed initial phase RCTs31-33 
and two subsequent RCTs.34,36 As for the three RCTs,31-33 pa-
tients with 1–3 historical failures in adequate antidepressant 
trials (total score ≥18 on the HAM-D17) were screened and 
then entered an 8-week prospective treatment phase. Incom-
plete responders were then randomized for treatment with 
either aripiprazole or placebo for 6 weeks. The primary effica-
cy endpoint was the mean change from baseline for the MADRS 
total score. In total 1,092 prospectively identified partial re-
sponders were randomized and 940 (86.4%) patients com-
pleted the 6-week three RCTs. In these three RCTs, significant 
improvements in the mean change of the MADRS total score 
(range=-8.5 to -10.1) with AA over placebo (-5.8 to -6.4) were 
observed.31-33 
OLSs
The pooled SMDs for the primary efficacy measure was sta-
tistically significant, pointing out the significant reduction of 
depressive symptoms after aripiprazole augmentation to cur-
rent antidepressant treatment (pooled SMD=-2.114, z=-9.625, 
p<0.001) (Figure 2). The heterogeneity between OLSs was sig-
nificant, pointing out the substantial variability of in the mag-
nitude of treatment difference and underlying variance influ-
encing on the outcome (I2=80.1%, Q-value=60.3, p<0.001). 
The pooled SMD was repeatedly calculated and analyzed with 
omission of one study at a time to perform a sensitivity anal-
ysis; the pooled SMD of the primary efficacy measure ranged 
from -2.210 to -1.898 (all 95% CIs indicated the statistical sig-
nificance: range from -2.710 to -1.552), proposing that no one 
study has strongly impacted the pooled SMD. The Egger test 
was not statistically significant (t=2.114, p=0.055), indicating 
no publication bias.
RCTs
The pooled SMDs for the primary efficacy measure was sta-
tistically significant, pointing out the significant reduction of 
depressive symptoms after aripiprazole augmentation to cur-
rent antidepressant treatment (pooled SMD=-2.202, z=-6.862, 
p<0.001) (Figure 2). The heterogeneity between RCTs was 
significant, pointing out the substantial variability of in the 
magnitude of treatment difference and underlying variance 
influencing on the outcome (I2=94.3%, Q-value=70.6, p<0.001). 
The pooled SMD was repeatedly calculated and analyzed with 
omission of one study at a time to perform a sensitivity anal-
ysis; the pooled SMD of the primary efficacy measure ranged 
from -2.430 to -1.896 (all 95% CIs indicated the statistical sig-
nificance: range from -3.154 to -1.333), proposing that no one 
study has strongly impacted the pooled SMD. The Egger test 
Figure 2. A meta-analysis of the prima-
ry efficacy measure of open-label stud-
ies (OLSs) and randomized, placebo-
controlled trials (RCTs). The numbers of 
1 and 2 indicate study design, OLS and 
RCT, respectively. SMD: standardized 
mean difference, CIs: confidence inter-
vals.
SMDs and 95% CIs
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was not statistically significant (t=1.117, p=0.345), indicating 
no publication bias.
Aripiprazole vs. placebo SMDs for RCTs
The pooled SMDs for the primary efficacy measure was sta-
tistically significant, pointing out the significant reduction of 
depressive symptoms after aripiprazole augmentation vs. pla-
cebo to current antidepressant treatment (pooled SMD=-2.182, 
z=-3.135, p=0.002) (Figure 3). The heterogeneity was also 
significant, pointing out the substantial variability of in the 
magnitude of treatment difference and underlying variance 
influencing on the outcome among study (I2=98.8%, Q-val-
ue=341.7, p<0.001). The pooled SMD was repeatedly calcu-
lated and analyzed with omission of one study at a time to 
perform a sensitivity analysis; the pooled SMD of the prima-
ry efficacy measure ranged from -2.673 to -1.655 (all 95% CIs 
indicated the statistical significance: range from -4.025 to 
-0.255), proposing that no one study has strongly impacted the 
pooled SMD. The Egger test was not statistically significant 
(t=0.416, p=0.705), indicating no publication bias.
Meta-regression
Meta-regression was performed to test the effect of study 
design (OLSs vs. RCTs) as an independent parameter on the 
mean change in the primary efficacy measure. There was no 
evidence of statistical difference in the pooled SMDs for the 
primary efficacy measure between OLSs and RCTs (t=0.119, 
p=0.737), suggesting no substantial influence of design on 
the primary treatment outcome. However, the pooled SMD 
was numerically higher in RCTs (-2.202, 95% CIs=-2.831, 
-1.573) than in OLSs (-2.114, 95% CIs=-2.545, -1.684). Given 
aforementioned results, the overall pooled SMDs between 
the two designs were sufficiently resembling each other and 
the correlation between the two design of pooled SMDs were 
0.714, indicating a similarity of the results between such two 
designs. 
DISCUSSION
We tried to find any useful and informative data between 
the two study designs for AA, OLS and RCT, in the treatment 
of MDD: OLS may have a potential utility to guide the RCT 
for proving the effect of AA in the treatment of MDD. Ac-
cording to our results, the pooled SMDs for the primary effi-
cacy measure was statistically significant in both study design, 
showing a significant reduction of depressive symptoms after 
AA treatment to current antidepressant treatment in OLSs 
and in RCTs. The effect sizes measured by SMDs between 
OLS and RCT design was quite similar and adequately corre-
lated, indicating a practical utility of OLS design to move to 
RCT conduction in the treatment of MDD. When sensitivity 
analyses show that the overall result and conclusions are not 
affected by the different decisions that could be made during 
the review process, the results of the review can be regarded 
with a higher degree of certainty. Where sensitivity analyses 
identify particular decisions or missing information that greatly 
influence the findings of the review, greater resources can be 
deployed to try and resolve uncertainties and obtain extra in-
formation, possibly through contacting trial authors and ob-
tained individual patient data.37 If this cannot be achieved, the 
results must be interpreted with an appropriate degree of cau-
tion. Such findings may generate proposals for further inves-
tigations and future research.37 In addition, no publication bi-
ases were found in the present meta-analysis, indicating the 
validity of the results of a meta-analysis results; if not so, no 
matter how systematic and thorough in other respects in me-
ta-analysis, the results are not confident.37 Our meta-regres-
sion analysis clearly revealed no influence of the study design 
on for treatment outcome, proving that study design would 
not have any role as a predictor to the primary treatment 
outcome.17 
Our results are in line with the previous meta-analysis found 
similarities in the treatment effects between OLS and RCTs 
in youth with bipolar disorder indicating that studies with 
open-label design are useful predictors of the potential safety 
Figure 3. A meta-analysis of the primary 
efficacy measure of aripiprazole versus 
placebo in randomized, placebo-con-
trolled trials. SMD: standardized mean 
difference, CIs: confidence intervals.
SMDs and 95% CIs
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and efficacy of a given compound in the treatment of pediat-
ric bipolar disorder, which was the first meta-analysis inves-
tigating such design issue in psychiatry.38 In the study, the 
pooled effect size was statistically significant in both OLSs 
(z=8.88, p<0.001) and RCTs (z=13.75, p<0.001), indicating a 
significant reduction in the Young Mania Rating Scale (YMRS) 
from baseline to the end of treatment in both study designs. 
The meta- regression also confirmed that study design was not 
a significant predictor of mean change in the YMRS. There-
fore, our meta-analysis clearly replicated the previous findings 
by Biederman et al that study design would not affect treat-
ment outcome and OLS may be a substantial indicator to lead 
a subsequent RCT to fully address a certain medication’s efficacy. 
Recently, there have been a number of evolving meta-ana-
lytic approaches to investigate clinically critical and very in-
formative issues in terms of study design implicated in clinical 
practice as well. For instance, placebo-response rates that is 
challenging obstacles for new treatment development in MDD 
(according to the results, relative efficacy of the active drug 
compared to placebo in clinical trials for MDD is highly het-
erogeneous across studies with different placebo response 
rates; the more placebo response the less performance of active 
drug),39 the application of a prospective lead-in trial phase to 
assess antidepressant nonresponse (historical data only to de-
fine treatment resistance prior to patient enrollment),40 impact 
of number of follow-up assessment (increasing the number 
of follow-up visits, specifically after the third week rather than 
within the first 3 week of the trial, may be an effective ap-
proach to improve the likelihood of trial success),40 the impact 
of study duration on treatment outcome (4 weeks is the mini-
mum adequate length of a trial), and starting dose issue of SS-
RIs (Higher starting dose higher response), e.t.c. These results 
deliver useful and valuable information to clinicians about 
the trial design as well as doing clinical practice. 
The most important clinical implication in terms of OLS 
and RCT design should be placed on the generalizability and 
external validity, since patients encountered in clinical prac-
tice often do not mirror populations of patients enrolled in 
well-controlled and adequately powered industry-sponsored 
or independent clinical trials.41 This emphasis has yielded large 
effectiveness trials such as the Sequenced Treatment Alterna-
tives to Relieve Depression (STAR*D) and the Clinical Anti-
psychotic Trials of Intervention Effectiveness (CATIE) trials 
designed to inform clinicians about the relative strengths of 
already existing but not fully investigated treatment ap-
proaches in the management of major psychiatric disorders. 
These studies aim to enroll typical community patients by 
having relatively lenient inclusion/exclusion criteria and con-
comitant medication restrictions, thus maximizing external 
validity. Hence, innovations in clinical trials methodology may 
stem from a handful of case reports and small-scale OLSs, 
which may be a useful transition process to RCT or further 
advanced, controlled clinical trials.41 Accordingly, OLS and 
RCT may have their own merits and limitations as a research 
methodology, by which we have to consider their complemen-
tary role to another one to have better and clear understand-
ing for achievement of advanced and innovative treatment 
tactics and strategies. 
The limitation of our results include: 1) the data base se-
arched in the present meta-analysis were confined to PubMed 
and PsychInfo, and published journals, so that we could not 
collect all the available clinical trial data, although our results 
did not show any evidence of publication bias and skew in 
sensitivity analyses 2) the clinical samples were adult popula-
tion and main portion was female 3) the mean duration was 
less than 10 weeks in both trial design, thus not be able to en-
sure any different results in longer-term clinical trials 4) the 
inclusion of different primary efficacy measure such as 
HAMD, MADRS and QIDS, although such rating scales are 
found to be highly correlated to each other, and finally 5) no 
inclusion of safety and tolerability measure due to their high 
variability in the measurement methods, by which we could 
not apply our results in such clinical issues.
In conclusion, we found that OLS for AA may be a useful 
indicator to conduct such time-consuming, complex and very 
expensive RCT in the treatment of MDD. Our results should 
be proved in other studies with different atypical antipsychot-
ics for the treatment of MDD as well. Furthermore, the value 
of OLS should be re-evaluated as one of crucial steps for de-
velopment of new drugs or acquisition for new indications.
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